

Technical Information


September 2016
Supersedes issue dated September 2008

03_030731e-05/Page 1 of 8
Last change WF-No. 131994

® = Registered trademark of BASF
in many countries.

Ludipress®

Excipient based on lactose monohydrate for direct tableting.



Nature

Ludipress® combines the three functionalities of a filler, binder and disintegrant in a ready-to-use excipient for tableting using the direct compression technology.

Ludipress® is composed of Lactose monohydrate, Povidone K30 (Kollidon® 30) and Crospovidone (Kollidon® CL).

It is a white, free-flowing granulated powder that is odorless and tasteless.

Specification

See separate document: "Standard Specification" (not for regulatory purposes) available via BASF's WorldAccount: <https://worldaccount.basf.com> (registered access).

Analytical methods

Lactose monohydrate is determined using a polarimetric assay. For Kollidon® CL a gravimetric method is in place. Kollidon® 30 is determined photometrically.

Analytical methods are available on request.

Hygroscopicity

Fig. 1 shows the sorption isotherm for Ludipress®, expressed in terms of the dry weight. The initial value corresponds practically to the hydrate water of the lactose.

Owing to the ability of the Kollidon® CL disintegrant to swell, irregular surfaces may be formed when tablets prepared with Ludipress® are exposed for long periods to high humidities.




Fig. 1: Sorption isotherm of Ludipress® at 30 °C

Grain size distribution

The following typical values are based on measurements using a screen tower:

15% max. < 63 μm
 40 – 60% < 200 μm
 90% min. < 400 μm

Fig. 2 shows an example of a particle size distribution as determined by laser diffraction techniques and dry sample preparation.




Fig. 2: Ludipress® particle size distribution as measured by laser diffraction techniques

Tabletting properties

Fig. 3 shows the behaviour of Ludipress® in the press in comparison to a physical mixture of the same composition.




Fig. 3: Ludipress® Compression behavior in comparison to a physical mixture

Regulatory status

No monographs exist.
The components Lactosemonohydrate and Povidon K30 (Kollidon® 30) are specified according to the current versions of Ph. Eur., USP and JP.

Microbiological status

The microbiological status is determined according to Ph. Eur. 2.6.12:

less than 1,000 viable aerobic counts/g
less than 100 yeasts and fungi/g
Absence of pathogenic nuclei
E. coli/g
Salmonella/10 g
Pseudomonas aeruginosa/g
Staphylococcus aureus/g
less than 100 other entero bacteria/g

Application

Ludipress® has been specially developed for direct tableting, but is also very suitable as a filler for hard gelatine capsules.

The addition of a disintegrant may be indicated when there is a high amount of active matter in the formulation. Also an addition of a dry binder like Kollidon® VA 64 Fine may improve tablet hardness in this case.

The following examples of formulations may serve as a guideline. A rotary tableting press was used at the compaction force indicated in each formulation.

Formulation 1**Acetylsalicylic Acid Tablets (400 mg)**

Acetylsalicylic acid, crystalline	400 g
Ludipress®	99 g
Stearic acid	1 g
Kollidon® CL	15 g

Mix all components, pass through a 0.8 mm sieve and press with low compression force.

Tablet properties

Weight	516 mg
Diameter	12 mm
Form	biplanar
Hardness	90 N
Disintegration	<1 min
Friability	0.4%
Dissolution, 10 min	84%
30 min	97%

Chemical stability

Storage time	RT	40 °C
0 months	100.0%	100.0%
16 months	100.0%	100.0%
12 months	98.4%	99.1%

The content of free salicylic acid remained always below 0.2%.

Formulation 2**Vitamin E Chewable Tablets (100 mg)**

Vitamin E acetate SD 50	200 g
Ludipress®	493 g
Aerosil 200	7 g

Mix all components, pass through a 0.8 mm screen and press with high compression force.

Properties

Weight	727 mg
Diameter	12 mm
Form	biplanar
Hardness	102 N
Disintegration	15 min
Friability	0%

Formulation 3**Ibuprofen Tablets (400 mg)**

I. Ibuprofen	400 g
Aerosil 200	4 g
II. Ludipress®	342 g
Kollidon® CL	8 g
Magnesium stearate	8 g

Mix I, add the components of II, and press with low compression force.

Properties

Weight	727 mg
Diameter	16 mm
Form	biplanar
Hardness	112 N
Disintegration	2 – 3 min
Friability	0.4%
Dissolution, 10 min	82%
15 min	91%

Physical stability (20 – 25 °C)

	6 Months	8 Months	12 Months
Hardness	–	121 N	120 N
Disintegration	–	2 – 3 min	–
Friability	0.4%	0.4%	0.2%
Dissolution, 10 min	85%	–	89%
20 min	87%	91%	88%

Formulation 4**Famotidine Tablets (40 mg)**

	No. 1	No. 2
Famotidine	40 g	40 g
Ludipress®	105 g	104 g
Magnesium stearate	3 g	–
Stearic acid	–	2 g
Aerosil 200	4 g	4 g

Mix all components, pass through a 0.8 mm sieve and press with low compression force.

Properties

	No. 1	No. 2
Weight	149 mg	148 mg
Diameter	8 mm	8 mm
Form	biplanar	biplanar
Hardness	74 N	49 N
Disintegration (gastric juice)	3 min	1 min
Friability	< 0.1%	0.3%
Dissolution, 10 min	63%	not tested
30 min	95%	not tested

Formulation 5**Glibenclamide Tablets (5 mg)**

	No. 1	No. 2
Glibenclamide, micronized	5.0 g	–
Glibenclamide	–	5.0 g
Ludipress®	120.0 g	194.0 g
Magnesium stearate	0.5 g	1.0 g

Mix all components, pass through a 0.8 mm sieve and press with low compression force (about 10 kN).

Properties

	No. 1	No. 2
Weight	125 mg	201 mg
Diameter	7 mm	8 mm
Form	biplanar	biplanar
Hardness	80 N	107 N
Disintegration	2 – 3 min	3 – 4 min
Friability	< 0.2%	< 0.1%
Dissolution, 10 min	50%	–
30 min	69%	–
60 min	75%	–

Influence of the compression force on the physical tablet properties (No. 2)

	Compression force			
	5 kN	10 kN	20 kN	25 kN
Hardness	47 N	107 N	158 N	191 N
Disintegration	2 – 3 min	3 – 4 min	3 – 4 min	5 min
Friability	< 0.1%	< 0.1%	< 0.1%	< 0.1%

Formulation 6**Propranolol Hydrochloride Tablets (10 mg, 50 mg and 100 mg)**

	No. 1	No. 2	No. 3
Propranolol hydrochloride	10 g	50 g	100 g
Ludipress®	490 g	450 g	400 g
Magnesium stearate	2.5 g	2.5 g	2.5 g

Mix all components, pass through a 0.8 mm sieve and press with low compression force.

Properties

	No. 1	No. 2	No. 3
Weight	514 mg	496 mg	505 mg
Diameter	12 mm	12 mm	12 mm
Form	biplanar	biplanar	biplanar
Hardness	112 N	86 N	101 N
Disintegration	2 min	2 min	3 min
Friability	0.1%	0.2%	0.1%

Remarks

– In the case of formulation No. 1 or No. 2 the amount of Ludipress® and the tablet weight may be reduced.

These formulations may be also used for tablet cores.

Formulation 7**Vitamin C Tablets (200 mg), Addition of Dry Binder Kollidon® VA 64**

	No. 1	No. 2
Ascorbic acid, powder	200.0 g	200.0 g
Ludipress®	256 g	256.0 g
Kollidon® VA 64	–	25.0 g
Magnesium stearate	2.5 g	2.5 g

Mix all components, pass through a 0.8 mm screen and press with medium compression force (18 kN).

Properties

	No. 1	No. 2
Weight	475 mg	499 mg
Diameter	12 mm	12 mm
Form	biplanar	biplanar
Hardness	56 N	73 N
Friability	3.2%	0.4%
Dissolution, 30 min	> 90%	> 90%

Formulation 8**Multivitamin Tablets**

Vitamin A Acetate Dry Powder 500.00 I. U./g	10.0 g
Thiaminmononitrate	2.2 g
Riboflavin	2.2 g
Nicotinamide	16.5 g
Calcium D-pantothenate	11.0 g
Pyridoxinhydrochloride	2.2 g
Cyanocobalamine 0.1% SD	6.0 g
Ascorbic Acid, Powder	85.0 g
Vitamin E Acetate Dry Powder SD 50	31.0 g
Ludipress®	321.0 g
Magnesium stearate	3.0 g
Saccharin-Sodium	2.5 g
Orange Flavor	7.2 g

Mix all components, pass through a 0.8 mm sieve and press with a medium compression force.

Properties

Weight	500 mg
Diameter	12 mm
Form	biplanar
Hardness	68 N
Disintegration	5 min
Friability	0.2%

Packaging

20 kg cardboard boxes with PE inner liners

Storage

Keep containers tightly closed at <25 °C.

Storage stability

Retest period of the product in original unopened containers is at least 24 months if they are properly stored.

PRD-No.

30034982

Disclaimer

This document, or any answers or information provided herein by BASF, does not constitute a legally binding obligation of BASF. While the descriptions, designs, data and information contained herein are presented in good faith and believed to be accurate, it is provided for your guidance only. Because many factors may affect processing or application/use, we recommend that you make tests to determine the suitability of a product for your particular purpose prior to use. It does not relieve our customers from the obligation to perform a full inspection of the products upon delivery or any other obligation. NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARE MADE REGARDING PRODUCTS DESCRIBED OR DESIGNS, DATA OR INFORMATION SET FORTH, OR THAT THE PRODUCTS, DESIGNS, DATA OR INFORMATION MAY BE USED WITHOUT INFRINGING THE INTELLECTUAL PROPERTY RIGHTS OF OTHERS. IN NO CASE SHALL THE DESCRIPTIONS, INFORMATION, DATA OR DESIGNS PROVIDED BE CONSIDERED A PART OF OUR TERMS AND CONDITIONS OF SALE.

September 2016